Outset Medical (OM) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic overview and market positioning

• Operates in large healthcare markets, with 90 million annual dialysis treatments and a $73 billion U.S. spend, focusing on transforming dialysis delivery from hospital to home using Tablo technology.

• Tablo is installed in about 850 U.S. facilities, delivering over a million treatments annually, with more than 60% of revenue from recurring sources like consumables and service.

• Commercial strategy targets acute and home markets, with channels including hospitals, critical access hospitals, mid-size dialysis organizations, and skilled nursing facilities.

• Sales transformation in 2024 included changes to salesforce, process, and pipeline management, positioning for renewed growth in 2025.

• Entered 2025 with a strengthened balance sheet after $169 million equity financing and debt refinancing, extending debt maturity to 2030.

Technology and competitive advantages

• Tablo eliminates the need for water treatment rooms, offering a compact, all-in-one dialysis solution that reduces cost and complexity.

• System transmits 3 million data points per treatment, surpassing 1 trillion data points in aggregate, supporting R&D and remote diagnostics.

• Designed for ease of use, with consumer-friendly features, automation, and a form factor suitable for home use.

• First device in the acute space fully integrated with Epic and Cerner EMRs, enabling future software and interoperability revenue streams.

Economic impact and clinical outcomes

• Hospitals can reduce dialysis costs by 50%-80% by insourcing with Tablo, mainly through labor and supply savings.

• Published studies show $550 per treatment savings and reduced ICU length of stay by up to five days.

• Contracted with all major LTCH, rehab providers, and the largest health systems, with over 10,000 nurses and 1,000 physicians trained.